These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 38336227)

  • 1. Global distribution of heterogeneous vancomycin-intermediate Staphylococcus aureus strains (1997-2021): a systematic review and meta-analysis.
    Keikha M; Karbalaei M
    J Glob Antimicrob Resist; 2024 Jun; 37():11-21. PubMed ID: 38336227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence and molecular characteristics of heterogeneous vancomycin intermediate Staphylococcus aureus in a tertiary care center of northern China.
    Cheng X; Ma L; Wang Y; Sun W; Su J
    Diagn Microbiol Infect Dis; 2024 Mar; 108(3):116180. PubMed ID: 38183897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular epidemiology and clinical characteristics of hetero-resistant vancomycin intermediate Staphylococcus aureus bacteremia in a Taiwan Medical Center.
    Lin SY; Chen TC; Chen FJ; Chen YH; Lin YI; Siu LK; Lu PL
    J Microbiol Immunol Infect; 2012 Dec; 45(6):435-41. PubMed ID: 22749725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA among methicillin-resistant S. aureus with high vancomycin minimal inhibitory concentrations in Taiwan: A multicenter surveillance study, 2012-2013.
    Huang SH; Chen YC; Chuang YC; Chiu SK; Fung CP; Lu PL; Wang LS; Wu TL; Wang JT
    J Microbiol Immunol Infect; 2016 Oct; 49(5):701-707. PubMed ID: 26320398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic Review and Meta-Analysis of the Epidemiology of Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Isolates.
    Zhang S; Sun X; Chang W; Dai Y; Ma X
    PLoS One; 2015; 10(8):e0136082. PubMed ID: 26287490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigation of heteroresistant vancomycin intermediate Staphylococcus aureus among MRSA isolates.
    Gazel D; Erinmez M; Büyüktaş Manay A; Zer Y
    J Infect Dev Ctries; 2021 Jan; 15(1):89-94. PubMed ID: 33571150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular and Clinical Features of Heterogeneous Vancomycin-Intermediate
    Sreejisha M; Shenoy MS; Shenoy MS; Dhanashree B; Chakrapani M; Bhat KG
    Sultan Qaboos Univ Med J; 2023 Nov; 23(4):447-454. PubMed ID: 38090245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High frequency of SCCmec type V and agr type I among heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) in north India.
    Singh A; Prasad KN; Rahman M; Rai RP; Singh SK; Srivastava JK
    J Glob Antimicrob Resist; 2017 Mar; 8():110-114. PubMed ID: 28109847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vancomycin and daptomycin minimum inhibitory concentration distribution and occurrence of heteroresistance among methicillin-resistant Staphylococcus aureus blood isolates in Turkey.
    Sancak B; Yagci S; Gür D; Gülay Z; Ogunc D; Söyletir G; Yalcin AN; Dündar DO; Topçu AW; Aksit F; Usluer G; Ozakin C; Akalin H; Hayran M; Korten V
    BMC Infect Dis; 2013 Dec; 13():583. PubMed ID: 24325260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Etest Methods for Screening Heterogeneous Vancomycin-Intermediate Staphylococcus aureus (hVISA) strains.
    Lee MY; Lee WI; Kim MH; Kang SY; Kim YJ
    Curr Microbiol; 2020 Oct; 77(10):3158-3167. PubMed ID: 32734419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High prevalence of a globally disseminated hypervirulent clone, Staphylococcus aureus CC121, with reduced vancomycin susceptibility in community settings in China.
    Shen P; Zhou K; Wang Y; Song J; Liu Y; Zhou Y; Xiao Y
    J Antimicrob Chemother; 2019 Sep; 74(9):2537-2543. PubMed ID: 31203362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Global prevalence and distribution of vancomycin resistant, vancomycin intermediate and heterogeneously vancomycin intermediate Staphylococcus aureus clinical isolates: a systematic review and meta-analysis.
    Shariati A; Dadashi M; Moghadam MT; van Belkum A; Yaslianifard S; Darban-Sarokhalil D
    Sci Rep; 2020 Jul; 10(1):12689. PubMed ID: 32728110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the Presence and Characterization of Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Level Resistance Among Bloodstream Isolates of Methicillin-Resistant
    Ozmen Capin BB; Tekeli A; Karahan ZC
    Microb Drug Resist; 2020 Mar; 26(3):238-244. PubMed ID: 31545160
    [No Abstract]   [Full Text] [Related]  

  • 14. Genotype-specific prevalence of heterogeneous vancomycin-intermediate Staphylococcus aureus in Asian countries.
    Chung DR; Lee C; Kang YR; Baek JY; Kim SH; Ha YE; Kang CI; Peck KR; Lee NY; Song JH
    Int J Antimicrob Agents; 2015 Sep; 46(3):338-41. PubMed ID: 25982914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterogeneous vancomycin-intermediate susceptibility phenotype in bloodstream methicillin-resistant Staphylococcus aureus isolates from an international cohort of patients with infective endocarditis: prevalence, genotype, and clinical significance.
    Bae IG; Federspiel JJ; Miró JM; Woods CW; Park L; Rybak MJ; Rude TH; Bradley S; Bukovski S; de la Maria CG; Kanj SS; Korman TM; Marco F; Murdoch DR; Plesiat P; Rodriguez-Creixems M; Reinbott P; Steed L; Tattevin P; Tripodi MF; Newton KL; Corey GR; Fowler VG;
    J Infect Dis; 2009 Nov; 200(9):1355-66. PubMed ID: 19811099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The incidence and risk factors for heterogeneous vancomycin intermediate Staphylococcus aureus].
    Feng NN; Wang Q; Song YL; He LX; Zhou CM; Xie HM; Li HY
    Zhonghua Nei Ke Za Zhi; 2013 Apr; 52(4):318-22. PubMed ID: 23925360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of heterogeneous vancomycin-intermediate
    Amberpet R; Sistla S; Sugumar M; Nagasundaram N; Manoharan M; Parija SC
    Indian J Med Res; 2019 Aug; 150(2):194-198. PubMed ID: 31670275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relevance of vancomycin-intermediate susceptibility and heteroresistance in methicillin-resistant Staphylococcus aureus bacteraemia.
    Khatib R; Jose J; Musta A; Sharma M; Fakih MG; Johnson LB; Riederer K; Shemes S
    J Antimicrob Chemother; 2011 Jul; 66(7):1594-9. PubMed ID: 21525024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Prevalence of Vancomycin-Intermediate Staphylococcus aureus and Heterogeneous VISA Among Methicillin-Resistant Strains Isolated from Pediatric Population in a Turkish University Hospital.
    Mirza HC; Sancak B; Gür D
    Microb Drug Resist; 2015 Oct; 21(5):537-44. PubMed ID: 25919019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomic insights on heterogeneous resistance to vancomycin and teicoplanin in Methicillin-resistant Staphylococcus aureus: A first report from South India.
    Bakthavatchalam YD; Babu P; Munusamy E; Dwarakanathan HT; Rupali P; Zervos M; John Victor P; Veeraraghavan B
    PLoS One; 2019; 14(12):e0227009. PubMed ID: 31887179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.